Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme (HALO – Research Report), with a price target of ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares ...

Principal Financial Group Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 25.7% during the 3rd quarter, according to its most recent filing with the SEC.

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...

(RTTNews) - Halozyme Therapeutics (HALO) announced that Takeda received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and Welfare for patients with agammaglobulinemia ...